Printer Friendly

SYNERGEN TO PRESENT ANTRIL PHASE III SEPSIS TRIAL RESULTS

 BOULDER, Colo., Feb. 22 /PRNewswire/ -- Synergen, Inc. (NASDAQ: SYGN) said today that the preliminary results of its Phase III clinical trial of ANTRIL(TM) in patients with sepsis will be presented on March 23 at the 13th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium.
 In the recently completed, double-blind study, 893 patients received either placebo or one of two different dose levels of ANTRIL for three days (along with the standard therapy of antibiotics and other supportive care). Patients who received placebo had a mortality rate of 34 percent. The mortality rate in patients who received the low dose of ANTRIL was 31 percent and patients in the group who received the high dose of ANTRIL had a mortality rate of 29 percent. The preliminary analysis of the clinical trial results included a favorable overall assessment of the safety profile.
 The company's preliminary analysis of the results indicates that the percentage reduction in mortality rate in the ANTRIL group depends on the severity of disease. The benefit of ANTRIL appears to increase with increasing severity of illness as judged by parameters that can be readily determined at the time of treatment. For example, one-half to two-thirds of the patients assessed as being most seriously ill showed a 20-25 percent reduction in mortality in the groups treated with ANTRIL. For these patients, the placebo group had a mortality rate similar to that seen in the placebo group in the Phase II trial.
 Jon S. Saxe, president and chief executive officer stated that, "Initial analysis of the results demonstrated that ANTRIL reduced mortality in patients with sepsis, although we were disappointed that the results did not match those of the earlier trial. Based on these preliminary results, ANTRIL appears to benefit those patients who have the highest risk of death from sepsis.
 "Synergen is aggressively continuing its clinical development program for ANTRIL in sepsis, as well as other indications including rheumatoid arthritis, asthma, psoriasis and several other inflammatory conditions," Saxe added.
 This past weekend, the company unblinded the data and performed its initial analyses. During the next several months, the company will carry out detailed safety and efficacy analyses of the data. The submissions required for approval by the Food and Drug Administration and foreign regulatory agencies have not yet been made and must await the complete analysis of the results and discussions with these agencies.
 Sepsis is the clinical complex of signs and symptoms that result from severe systemic infection. ANTRIL is a recombinant version of a naturally occurring protein known as an interleukin-1 receptor antagonist. Interleukin-1 (IL-1) has been shown to be a major mediator of inflammatory response. Because ANTRIL blocks the action of IL-1, it is being tested as a new therapy for sepsis and other inflammatory disorders.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals. The company's research is targeted towards products for inflammatory diseases, tissue repair and neurological diseases. The company is headquartered in Boulder, with manufacturing operations in Boulder and Delaware, and business operations in the Netherlands and Japan.
 -0- 2/22/93
 /CONTACT: Paul Laland, 303-541-1325, or (investor) Debra Bannister, 303-938-6242, both of Synergen, Inc./
 (SYGN)


CO: Synergen, Inc. ST: Colorado IN: MTC SU:

TS -- NY017 -- 8769 02/22/93 07:48 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 22, 1993
Words:549
Previous Article:MIPS ABI ANNOUNCES APPLICATIONS BINARY INTERFACE FOR MIPS RISC-BASED COMPUTER SYSTEMS
Next Article:ALCO INTERNATIONAL GROUP RECEIVES COPY OF SCHEDULE 13D
Topics:


Related Articles
SYNERGEN AND UNIVERSITY OF COLORADO AWARDED BROAD PATENT FOR INTERLEUKIN-1 RECEPTOR ANTAGONIST
SYNERGEN APPOINTS VICE PRESIDENTS OF MARKETING AND SALES AND PROCESS ENGINEERING
SYNERGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
SYNERGEN INC. REPORTS THIRD QUARTER FINANCIAL RESULTS
Chiron and Searle Initiate Plans for Pivotal Phase III Trial for Sepsis Compound.
Chiron Announces Results of Phase III Study of Tifacogin in Severe Sepsis.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters